The European Journal of Health Economics

, Volume 8, Supplement 2, pp 39–47

The burden of rheumatoid arthritis and access to treatment: a medical overview

Original paper

Abstract

As part of the investigation into the burden of rheumatoid arthritis (RA) and the access to treatment, this article reviews the medical aspects of the disease. RA is mediated by a variety of pathogenic events which culminate in the activation of B-cells, T-cells and other cell populations and lead to secretion of proinflammatory cytokines. These events result in signs and symptoms of active disease, such as pain and swelling, joint damage and disability, the three cornerstones of the clinical expression of RA. Active disease leads to joint damage and both to disability, whereby joint destruction is associated with the irreversible portion of disability. The diagnosis of RA is based on characteristic clinical and laboratory features, however, these may not be obvious in early disease. Therapy aims at interfering with disease activity, ideally leading to remission, as well as at retarding, ideally holding or even healing, joint destruction. This can be achieved by using disease modifying anirheumatic drugs (DMARDs). Among the chemical DMARDs, methotrexate is the anchor drug, although there exist many more such agents. Among the biological compounds, TNF-inhibitors have been in use for more than one decade, and co-stimulation blockade and B-cell targeted therapy have been recent additions to the armamentarium. Therapeutic outcome can be predicted by clinical means.

Keyword

Rheumatoid arthritis 

JEL Classification

A1 A10 A31 I11 

References

  1. 1.
    Silman A.J., Pearson J.E.: Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 4(Suppl 3), S265–S272 (2002)Google Scholar
  2. 2.
    MacKay, K., Eyre, S., Myerscough, A., Milicic, A., Barton, A., Laval, S. et al.: Whole-genome linkage analysis of rheumatoid arthritis susceptibility loci in 252 affected sibling pairs in the United Kingdom. Arthritis Rheum. 46, 632–639 (2002)Google Scholar
  3. 3.
    Gregersen, P.K., Silver, J., Winchester, R.J.: The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205–1213 (1987)Google Scholar
  4. 4.
    Gregersen, P.K.: Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. Immunol. Rev. 204, 74–86 (2005)Google Scholar
  5. 5.
    Remmers, E.F., Plenge, R.M., Lee, A.T., Graham, R.R., Hom, G., Behrens, T.W., et al.: STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357(10), 977–986 (2007)Google Scholar
  6. 6.
    Plenge, R.M., Seielstad, M., Padyukov, L., Lee, A.T., Remmers, E.F., Ding, B. et al.: TRAF1-C5 as a risk locus for rheumatoid arthritis–a genomewide study. N. Engl. J. Med. 357(12), 1199–209 (2007)Google Scholar
  7. 7.
    Gabriel S.E.: The epidemiology of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 27, 269–81 (2001)Google Scholar
  8. 8.
    Ebringer, A., Wilson, C.: HLA molecules, bacteria and autoimmunity. J. Med. Microbiol. 49, 305–11 (2000)Google Scholar
  9. 9.
    Krieg, A.M. A role for Toll in autoimmunity. Nat. Immunol. 3(5), 423–4 (2002)Google Scholar
  10. 10.
    Steiner, G., Smolen, J.S.: Autoantibodies in rheumatoid arthritis. In: Firestein, G.S., Panayi, G.S., Wollheim, F.A. (eds). 2 edn, pp. 193–198. Oxford University Press, Oxford (2006)Google Scholar
  11. 11.
    Bobacz, K., Sunk, I., Hofstaetter, J., Amoyo, L., Toma, C., Akira, S., et al.: Toll-like receptors and chondrocytes: the LPS induced decrease in cartilage matrix synthesis is dependent on the presence of Toll-like receptor-4 and is antagonized by bone morphogenetic protein-7. Arthritis Rheum. (in press, 2007)Google Scholar
  12. 12.
    Smolen, J.S., Aletaha, D., Koeller, M., Weisman, M., Emery, P.: New therapies for the treatment of rheumatoid arthritis. Lancet 370, 1861–1874 (2007)Google Scholar
  13. 13.
    Rodriguez-Pinto, D.: B cells as antigen presenting cells. Cell Immunol. 238(2), 67–75 (2005)Google Scholar
  14. 14.
    Dorner, T., Burmester, G.R.: The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. 15(3), 246–252 (2003)Google Scholar
  15. 15.
    Ravetch, J.V., Bolland, S.: IgG Fc receptors. Annu. Rev. Immunol. 19, 275–90 (2001)Google Scholar
  16. 16.
    Debets, J.M., Van der Linden, C.J., Dieteren, I.E., L.J., Buurman, W.A.: Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J. Immunol. 141, 1197–201 (1988)Google Scholar
  17. 17.
    Nielen, M.M., van der Horst, A.R., van Schaardenburg, D., van der Horst-Bruinsma, I.E., van de Stadt, R.J., Aarden, L. et al.: Antibodies to citrullinated human fibrinogen (acf) have diagnostic and prognostic value in early arthritis. Ann. Rheum. Dis. 64 (Jan 7):(Epub ahead of print, 2005)Google Scholar
  18. 18.
    Nell, V., Machold, K.P., Stamm, T.A., Eberl, G., Heinzl, H., Uffmann, M. et al.: Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann. Rheum. Dis. 64, 1731–1736 (2005) (Epub 2005 May 5)Google Scholar
  19. 19.
    Mattey, D.L., Dawes, P.T., Clarke, S., Fisher, J., Brownfield, A., Thomson, W. et al.: Relationship among the HLA-DRB1 shared epitope, smoking and rheumatoid factor production in rheumatoid arthritis. Arthritis Rheum. 47, 403–407 (2002)Google Scholar
  20. 20.
    van Gaalen, F.A., van Aken, J., Huizinga, T.W., Schreuder, G.M., Breedveld, F.C., Zanelli, E., et al.: Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 50, 2113–2121 (2004)Google Scholar
  21. 21.
    Steiner, G., Tohidast-Akrad, M., Witzmann, G., Vesely, M., Studnicka-Benke, A., Gal, A., et al.: Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 38, 202–213 (1999)Google Scholar
  22. 22.
    Feldmann, M., Brennan, F.M., Foxwell, B.M., Maini, R.N.: The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr. Dir. Autoimmun. 3, 188–199 (2001). Ref Type: Journal (Full)CrossRefGoogle Scholar
  23. 23.
    Keffer, J., Probert L.t al, Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D, et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10, 4025–31 (1991)Google Scholar
  24. 24.
    Partsch, G., Steiner, G., Leeb, B.F., Dunky, A., Broll, H., Smolen, J.S.: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24, 518–523 (1997). Ref Type: Journal (Full)Google Scholar
  25. 25.
    Martinez-Gamboa, L., Brezinschek, H.P., Burmester, G.R., Dorner, T.: Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun. Rev. 5(7), 437–442 (2006)Google Scholar
  26. 26.
    Duddy, M., Niino, M., Adatia, F., Hebert, S., Freedman, M., Atkins, H., et al.: Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178(10), 6092–6099 (2007)Google Scholar
  27. 27.
    Naka, T., Nishimoto, N., Kishimoto, T.: The paradigm of IL-6: from basic science to medicine. Arthritis. Res. 4(Suppl 3), S233–S242 (2002)Google Scholar
  28. 28.
    Teitelbaum, S.L.: Bone resorption by osteoclasts. Science 289, 1504–1508 (2000)Google Scholar
  29. 29.
    Lam, J., Takeshita, S., Barker, J.E., Kanagawa, O., Ross, F.P., Teitelbaum, S.L.: TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481–1488 (2000)Google Scholar
  30. 30.
    Redlich, K., Hayer, S., Ricci, R., David, J.P., Tohidast-Akrad, M., Kollias, G., et al.: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J. Clin. Invest. 110(10), 1419–1427 (2002)Google Scholar
  31. 31.
    Gravallese E.M.: Bone destruction in arthritis. Ann. Rheum. Dis. 61(Suppl 2), ii84–ii86 (2002) Ref Type: AbstractGoogle Scholar
  32. 32.
    Kong, Y.Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402(6759), 304–309 (1999)Google Scholar
  33. 33.
    Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., et al.: Connection etween B lymphocyte and osteoclast differentiation pathways. J. Immunol. 167(5), 2625–2631 (2001)Google Scholar
  34. 34.
    Folkman J.: Angiogenesis. In: Smolen J.S., Lipsky P.E. (eds) Targeted Therapies in Rheumatology, pp. 111–131. Martin Dunitz, London (2003)Google Scholar
  35. 35.
    Haringman, J.J., Oostendorp, R.L., Tak, P.P.: Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. Expert Opin. Emerg. Drugs 10(2), 299–310 (2005)Google Scholar
  36. 36.
    Szekanecz Z., Kim J., Koch A.E.: Chemokines. In: Smolen J.S., Lipsky P.E. (eds) Targeted Therapies in Rheumatology, pp. 345–357. Martin Dunitz, London (2003)Google Scholar
  37. 37.
    Aletaha, D., Smolen, J., Ward, M.M.: Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum. 54, 2784–2792 (2006)Google Scholar
  38. 38.
    Sherrer, Y.S., Bloch, D.A., Mitchell, D.M., Yound, D.Y., Fries, J.F.: The development of disability in rheumatoid arthritis. Arthritis Rheum. 29, 494–500 (1986)Google Scholar
  39. 39.
    Scott, D.L., Symmons, D.P., Coulton, B.L., Popert, A.J.: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1(8542), 1108–1111 (1987)Google Scholar
  40. 40.
    Drossaers-Bakker, K.W., de Buck, M., van Zeben, D., Zwinderman, A.H., Breedveld, F.C., Hazes, J.M.: Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42, 1854–1860 (1999)Google Scholar
  41. 41.
    Machold, K.P., Stamm, T.A., Nell, V.P., Pflugbeil, S., Aletaha, D., Steiner, G., et al.: Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006)Google Scholar
  42. 42.
    Kraan, M.C., Versendaal, H., Jonker, M., Bresnihan, B., Post, W.J., t Hart, B.A., Breedveld, F.C., et al.: Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 41, 1481–1488 (1998). Ref Type: Journal (Full)Google Scholar
  43. 43.
    Aho, K., Heliovaara, M., Maatela, J., Tuomi, T., Palusuo, T. Rheumatoid factors antedating clinical rheumatoid arthritis. J. Rheumatol. 18, 1282–1284 (1991) Ref Type: Journal (Full)Google Scholar
  44. 44.
    Aho, K., von Essen, R., Kurki, P., Palusuo, T., Heliovaara, M.: Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J. Rheumatol. 20, 1278–1281 (1993) Ref Type: Journal (Full)Google Scholar
  45. 45.
    Rantapaa-Dahlqvist, S., de Jong, B.A., Berglin, E., Hallmans, G., Wadell, G., Stenlund, H., et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741–2749 (2003)Google Scholar
  46. 46.
    Hayer, S., Redlich, K., Korb, A., Hermann, S., Smolen, J., Schett, G.: Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum. 56, 79–88 (2007)Google Scholar
  47. 47.
    Smolen, J.S., AletahaD, Machold, K., Nell, V., Redlich, K., Schett, G., et al.: Prearthritis—a concept whose time has come. Future Rheumatol. 1, 1–4 (2006)Google Scholar
  48. 48.
    Masi, A.T.: Articular patterns in the early course of rheumatoid arthritis. Am. J. Med. 75, 16–26 (1983)Google Scholar
  49. 49.
    Smolen, J.S., Breedveld, F.C., Eberl, G., Jones, I., Leeming, M., Wylie, G.L., et al.: Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 38(1), 38–43 (1995)Google Scholar
  50. 50.
    Ware, J.E. J, Sherbourne, C.D.: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473–483 (1992)Google Scholar
  51. 51.
    Wolfe, F.E., Hawley, D.J.: The longterm outcome of rheumatoid arthritis. Work disability: a prospective 18 year study of 816 patients. J. Rheumatol. 25, 2108–2117 (1998)Google Scholar
  52. 52.
    Sokka, T., Kautiainen, H., Mottonen, T., Hannonen, P.: Work disability in rheumatoid arthritis 10 years after the diagnosis. J. Rheumatol. 26(8):1681–1685 (1999)Google Scholar
  53. 53.
    Pincus, T., Callahan, L.F.: What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19, 123–1251 (1993)Google Scholar
  54. 54.
    Wolfe, F.: The natural history of rheumatoid arthritis. J. Rheumatol. 44(Suppl):13–22 (1996)Google Scholar
  55. 55.
    Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54(3):692–701 (2006)Google Scholar
  56. 56.
    Wolfe, F., Michaud, K.: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116, 305–311 (2004). Ref Type: AbstractGoogle Scholar
  57. 57.
    Choi, H.K., Hernan, M.A., Seeger, J.D., Robins, J.M., Wolfe, F.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359(9313), 1173–1177 (2002)Google Scholar
  58. 58.
    Pincus, T., Callahan, L.F.: Early mortality in RA predicted by poor clinical status. Bull. Rheum. Dis. 41(4):1–4 (1992)Google Scholar
  59. 59.
    Machold, K.P., Stamm, T.A., Eberl G.J.M., Nell V.K.P., Dunky, A., Uffmann, M., et al.: Very recent onset arthritis—clinical, laboratory and radiological findings during the first year of disease. J. Rheumatol. 29, 2278–2287 (2002)Google Scholar
  60. 60.
    Green, M., Marzo-Ortega H., McGonagle D., Wakefield, R.J., Proudman, S.M., Conaghan, P.G., et al.: Persistence of mild, early inflammatory arthritis:the importance of disease duration, rheumatoid factor, and the shared epitope. Arthritis Rheum. 42, 2184–2188 (1999)Google Scholar
  61. 61.
    Green, M.J., Marzo-Ortega, H., Proudman, S., Karim, Z., Conaghan, P.G., Emery, P.: Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum. 48, 3039–3045 (2003). Ref Type: Journal (Full)Google Scholar
  62. 62.
    Tunn, E.J., Bacon, P.A.: Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. Br. J. Rheumatol. 32, 97–103 (1993)Google Scholar
  63. 63.
    Visser, H., le Cessie, S., Vos, K., Breedveld, F.C., Hazes, J.M.W.: How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 46, 357–365 (2002)Google Scholar
  64. 64.
    Emery, P., Breedveld, F.C., Dougados, M., Kalden, J.R., Schiff, M.H., Smolen, J.S.: Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum. Dis. 61, 290–297 (2002)Google Scholar
  65. 65.
    Ropes, M.W., Bennett, G.A., Cobb, S., Jacox, R., Jessar, R.A.: 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum. 2, 16–20 (1959). Ref Type: Journal (Full)Google Scholar
  66. 66.
    Arnett, F.C., Edworthy, S.M., Block, D.A., McShane D.J., Fries, J.F., Cooper, N.S., et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988). Ref Type: Journal (Full)Google Scholar
  67. 67.
    Aletaha, D., Breedveld, F.C., Smolen, J.S.: The need for new classification criteria for rheumatoid arthritis. Arthritis Rheum. 52, 3333–3336 (2005)Google Scholar
  68. 68.
    Aletaha, D., Eberl, G., Nell, V.P., Machold, K.P., Smolen, J.S.: Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within 3 years. Ann. Rheum. Dis. 61, 630–634 (2002)Google Scholar
  69. 69.
    Plant, M.J., Jones, P.W., Saklatvala, J., Ollier, W.E., Dawes, P.T.: Patterns of radiological progression in rheumatoid arthritis: results of an 8 year prospective study. J. Rheumatol. 25, 417–426 (1998)Google Scholar
  70. 70.
    Aletaha, D., Smolen, J.S.: DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease. Clin. Exp. Rheumatol. 21(Suppl 31), S169–S173 (2003). Ref Type: Journal (Full)Google Scholar
  71. 71.
    van der Heijde, D.M., van Riel, P.L., Nuver-Zwart, Gribnau, van de Putte, L.: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1, 1036–1038 (1989)Google Scholar
  72. 72.
    Weinblatt, M.E.: Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum. Dis. 62(Suppl ii), ii94–ii96 (2003). Ref Type: Journal (Full)Google Scholar
  73. 73.
    Pincus, T., Yazici, Y., Sokka, T., Aletaha, D., Smolen, J.S.: Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21(Suppl 31), S178–S185 (2003). Ref Type: Journal (Full)Google Scholar
  74. 74.
    Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Int. Med. 159, 2542–2550 (1999). Ref Type: GenericGoogle Scholar
  75. 75.
    Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353, 259–266 (1999)Google Scholar
  76. 76.
    Emery, P., Smolen, J.S.: Issues in rheumatoid arthritis. Lancet 353, 1186 (1999). Ref Type: GenericGoogle Scholar
  77. 77.
    O’Dell J.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 334, 1287–1291 (1996)Google Scholar
  78. 78.
    Smolen, J.S., Aletaha, D., Keystone, E.: Superior efficacy of combination therapy for rheumatoid arthritis. Fact or Fiction?. Arthritis Rheum. 52, 2975–2983 (2005)Google Scholar
  79. 79.
    Boers, M., Verhoeven, A.C., Markusse, H.M., van de Laar, M.A., Westhovens, R., van Denderen, J.C., et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis: a randomised trial. Lancet 350, 309–318 (1997)Google Scholar
  80. 80.
    Svensson, B., Boonen, A., Albertsson, K., van de Heijde, D., Keller, C., Hafstrom, I.: Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a 2-year randomized trial. Arthritis Rheum. 52, 3360–3370 (2005)Google Scholar
  81. 81.
    Kirwan, J.R.: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med. 333(3):142–146 (1995)Google Scholar
  82. 82.
    van Everdingen, A.A., Jacobs, J.W., Siewertsz Van Reesema, D.R., Bijlsma, J.W.: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. 136, 1–12 (2002) Ref Type: Journal (Full)Google Scholar
  83. 83.
    FDA. FDA guidance paper. (1999) Ref Type: GenericGoogle Scholar
  84. 84.
    Aletaha, D., Smolen, J.S.: The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 41(12), 1367–1374 (2002)Google Scholar
  85. 85.
    Aletaha, D., Smolen, J.S.: Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J. Rheumatol. 29(8):1631–1638 (2002)Google Scholar
  86. 86.
    Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9), 1552–1563 (1998)Google Scholar
  87. 87.
    Felson, D.T., Anderson, J.J., Boers, M., Bombardier, C., Furst, D., G.C. et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727–735 (1995)Google Scholar
  88. 88.
    Van der Heijde, D.M.F.M., van’t Hof, M., van Riel, P.L., van de Putte, L.B.A.: Development of a disease activity score based on judgement in clinical practice by rheumatologists. J. Rheumatol. 20, 579–581 (1993)Google Scholar
  89. 89.
    Prevoo, M.L.L., van’t Hof, M.A., Kuper, H.H., van de Putte, L.B.A., van Riel, P.L.C.M.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44–48 (1995)Google Scholar
  90. 90.
    Smolen, J.S., Breedveld, F.C., Schiff, M.H., Kalden, J.R., Emery, P., Eberl, G., et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42, 244–257 (2003)Google Scholar
  91. 91.
    Aletaha, D., Nell, V.P.K, Stamm, T., Uffmann, M., Pflugbeil, S., Machold, K., et al.: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Res. 7, R796–R806 (2005)Google Scholar
  92. 92.
    Aletaha, D., Smolen, J.S.: The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum. Dis. Clin. North Am. 32, 9–44 (2006)Google Scholar
  93. 93.
    Fries J.F., Spitz P., Kraines, R.G., Holman, H.R.: Measurement of patient outcome in arthritis. Arthritis Rheum. 23, 137–145 (1980)Google Scholar
  94. 94.
    Sharp, J.T., Lidsky, M.D., Collins, L.C., Moreland, J.: Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. 14(6), 706–720 (1971)Google Scholar
  95. 95.
    Smolen, J.S., Aletaha, D.: What should be our treatment goal in rheumatoid arthritis today? Clin. Exp. Rheumatol. (2006, this issue)Google Scholar
  96. 96.
    Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400–1411 (2004)Google Scholar
  97. 97.
    Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., Cohen, S.B., Pavelka, K., van Vollenhoven, R., et al.: The PREMIER study—a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006)Google Scholar
  98. 98.
    Klareskog, L., van der Heijde, D., de Jager, J.P., Gough, A.K.J., Malaise, M., Martin-Mola, E., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004). Ref Type: Journal (Full)Google Scholar
  99. 99.
    Lipsky, P.E., Van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., Kalden, J.R., et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343(22):1594–1602 (2000)Google Scholar
  100. 100.
    St Clair E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum. 50, 3432–3443 (2004)Google Scholar
  101. 101.
    Smolen J.S., Han C., Bala M., Maini R., Kalden J., van der Heijde D., et al.: Evidence of radiographic benefit of infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of the attract trial. Arthritis Rheum. 52, 1020–1030 (2005)Google Scholar
  102. 102.
    Redlich, K., Schett, G., Steiner, G., Hayer, S., Wagner, E.F., Smolen, J.S.: Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 48, 3308–3319 (2003). Ref Type: Journal (Full)Google Scholar
  103. 103.
    Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb double-blind, placebo-controlled, dose-ranging trial (DANCER). Arthritis Rheum. 54, 1390–1400 (2006)Google Scholar
  104. 104.
    Cohen, S., Emery, P., Greenwald, M., Dougados, M., Furie, R., Genovese, M., et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 2739–2806 (2006)Google Scholar
  105. 105.
    Kremer, J.M., Genant, H.K., Moreland, L.W., Russell, A.S., Emery, P., bud-Mendoza, C., et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865–876 (2006)Google Scholar
  106. 106.
    Genovese, M.C., Becker, J.C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114–1123 (2005)Google Scholar
  107. 107.
    Maini, R.N., Taylor, P.C., Szechinski, J., Pavelka, K., Broll, J., Balint, G., et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817–2829 (2006)Google Scholar
  108. 108.
    Nishimoto, N., Hashimoto, J., Miyasaka, N., Yamamoto, K., Kawa, S., Takeuchi, T., et al.: Blocking interleukin-6 (IL-6) by tocilizumab (A humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): evidence from a X-ray reader-blinded randomised controlled trial Arthritis Rheum. 52, 4109 (2005)Google Scholar
  109. 109.
    Puolakka, K., Kauttiainen, H., Mottonen, T., Hannonen, P., Hakala, M., Korpela, M., et al.: Predictors of productivity loss in early rheumatoid arthritis: a 5-year follow-up study. Ann. Rheum. Dis. 64, 130–133 (2005)Google Scholar
  110. 110.
    Smolen, J.S., Han, C., van der, H.D., Emery, P., Bathon, J.M., Keystone, E., et al.: Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 54(3), 716–722 (2006)Google Scholar
  111. 111.
    van der Heide A., Jacobs J.W., Bijlsma J.W., Heurkens A.H., Booma-Frankfort C., van der Veen M.J., et al.: The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124(8), 699–707 (1996)Google Scholar
  112. 112.
    Lard, L.R., Visser, H., Speyer, I., van der Horst-Bruinsma, I.E., Zwinderman, A.H., Breedveld, F.C., et al.: Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111, 446–451 (2001)Google Scholar
  113. 113.
    Emery, P., Salmon, M.: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 54, 944–947 (1995)Google Scholar
  114. 114.
    Nell, V., Machold, K.P., Eberl, G., Stamm, T.A., Uffmann, M., Smolen, J.S.: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 43, 906–914 (2004). Epub 2004 Apr 27Google Scholar
  115. 115.
    Grigor, C., Capell, H., Stirling, A., McMahon A.D., Lock, P., Vallance, R., et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364, 263–269 (2004)Google Scholar
  116. 116.
    Goekoop-Ruiterman, Y.P., De Vries-Bouwstra, J.K., Allaart, C.F., Van Zeben, D., Kerstens, P.J., Hazes, J.M., et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52, 3381–3390 (2005)Google Scholar
  117. 117.
    Mierau, M., Schoels, M., Gonda, G., Fuchs, J., Aletaha, D., Smolen, J.S.: Assessing remission in clinical practice. Rheumatology, Mar 6; (Epub ahead of print). (2007). Ref Type: Journal (Full)Google Scholar
  118. 118.
    Aletaha, D., Funovits, J., Keystone, E.C., Smolen, J.S.: Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 56(10), 3226–3235 (2007)Google Scholar
  119. 119.
    Landre-Beauvais, A.J. Doit-on admettre une nouvelle espece de Goutte sous la denomination de Goutte Asthenique Primitive? Paris, Brisson, An VIII; (1800)Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Division of Rheumatology, Internal Medicine IIIMedical University of ViennaViennaAustria

Personalised recommendations